Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Autolus Therapeutics ( (AUTL) ) has shared an announcement.
On June 2, 2025, Autolus Therapeutics plc released its UK Annual Report and Accounts for the year ending December 31, 2024, and announced its upcoming annual general meeting scheduled for June 26, 2025. Citibank, as the depositary bank for Autolus’s American Depositary Shares, began distributing voting materials to ADS holders, allowing them to instruct the bank on voting their shares, although there may be limitations affecting timely voting.
The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
Autolus Therapeutics is experiencing strong revenue growth and strategic geographic expansion, notably with AUCATZYL. However, the financial performance indicates significant profitability and cash flow challenges. Technical indicators suggest caution, and while corporate events bolster future prospects, financial sustainability issues and a negative P/E ratio weigh heavily on the stock’s overall score.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Average Trading Volume: 1,968,737
Technical Sentiment Signal: Sell
Current Market Cap: $465.7M
For an in-depth examination of AUTL stock, go to TipRanks’ Stock Analysis page.